Skip to main content
SpringerLink
Log in

Does fixed-dose sumatriptan/naproxen for migraine save costs?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was sponsored and conducted by GlaxoSmithKline.

Reference

  • Runken MC, et al. Migraine-Related Healthcare Resource Use and Costs for Subjects Prescribed Fixed-Dose Combination Sumatriptan/Naproxen Sodium vs. Single-Entity Oral Triptans in a Managed Care Population in the USA. Applied Health Economics and Health Policy : 8 Oct 2014. Available from: URL: http://doi.org/10.1007/s40258-014-0129-2

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Does fixed-dose sumatriptan/naproxen for migraine save costs?. PharmacoEcon Outcomes News 714, 18 (2014). https://doi.org/10.1007/s40274-014-1639-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1639-8

Search

Navigation